Chemokine blockade as a therapy for renal disease

Current Opinion in Nephrology and Hypertension

Volumn 9, Issue 3, 2000, Pages 225-232

  Rovin, Brad H ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; BINDARIT; BIOFLAVONOID; CHEMOKINE; CHEMOKINE RECEPTOR; CYTOKINE ANTIBODY; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FRACTALKINE; HEPARIN DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; PENTOXIFYLLINE; RANTES; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; VIRUS PROTEIN;

CHEMOTAXIS; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; NEPHRITIS; NONHUMAN; PATHOGENESIS; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN FAMILY; RECEPTOR BLOCKING; REVIEW;

CHEMOKINES; GENE EXPRESSION REGULATION; GENE THERAPY; HUMANS; IMMUNOTHERAPY; INFLAMMATION; KIDNEY DISEASES;

EID: 0034024026     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200005000-00004     Document Type: Review

References (70)

1. 1 Rovin BH, Phan LT. Chemotactic factors and renal inflammation. Am J Kidney Dis 1998; 31:1065-1084. An in-depth review that details the evolution of chemokine research in nephrology.
2. 2 Rollins BJ. Chemokines. Blood 1997; 90:909-928.
3. 3 Zlotnik A, Morales J, Hedrick JA. Recent advances in chemokines and chemokine receptors. Crit Rev Immunol 1999; 19:1-47. A comprehensive review of chemokines and chemokine receptors identified after lymphotactin.
4. 4 Karpus WJ, Kennedy KJ. MIP-1a and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J Leuk Biol 1997; 62:681-687.
5. 5 Cyster JG. Chemokines and cell migration in secondary lymphoid organs. Science 1999; 286:2098-2102. A succinct review of chemokines involved in lymphocyte trafficking.
6. ••]).
7. ••].
8. •] are the first investigations to use targeted disruption of a chemokine (MCP-1) gene to investigate its role in glomerulonephritis. A number of important issues are presented in these papers. Key findings are that the effects of MCP-1 may be confined to specific compartments within the kidney, that complete absence of MCP-1 is associated with significant but not complete protection from immune injury, and that MCP-1 deficiency may affect expression of other cytokines and chemokines.
9. •].
10. 10 Yokoyama H, Wada T, Furuichi K, Segawa C, Shimizu M, Kobayashi K, et al. Urinary levels of chemokines (MCAF/MCP-1, IL-8) reflect distinct disease activities and phases of human IgA nephropathy. J Leukoc Biol 1998; 63:93-499.
11. •] examine CC chemokines in a similar spectrum of human glomerulonephritis, but show a different distribution of MCP-1 within the glomerular and tubular compartments of the kidney.
12. 12 Romagnani P, Beltrame C, Annunziato F, Lasagni L, Luconi M, Galli G, et al. Role for interactions between IP-10/Mig and CXCR3 in proliferative glomerulonephritis. J Am Soc Nephrol 1999; 10:2518-2526. The observation of a marked increase in CXCR3 expression in proliferative glomerulonephritis is followed up with studies in cultured human mesangial cells showing that CXCR3 ligands induce proliferation of these cells. This study suggests that CXCR3 antagonists may have a role in controlling glomerular cell proliferation.
13. 13 Schneider A, Panzer U, Zahner G, Wenzel U, Wolf G, Thaiss F, et al. Monocyte chemoattractant protein-1 mediates collagen deposition in experimental glomerulonephritis by transforming growth factor-β. Kidney Int 1999; 56:135-144. Using the anti-thymocyte glomerulonephritis model, the authors suggest a pathogenic role for MCP-1 in renal fibrosis that may not be dependent on recruiting inflammatory cells.
14. 14 Lloyd CM, Minto AW, Dorf ME, Proudfoot A, Wells TNC, Salant DJ, Gutierrez-Ramos J-C. RANTES and monocyte chemoattractant protein-1 play an important role in the inflammatory phase of crescentic nephritis but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 1997; 185:1371-1380.
15. 15 Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor B1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996; 271:17779-17784.
16. 16 Banas B, Luckow B, Moller M, Klier C, Nelson PJ, Schadde E, et al. Chemokine and chemokine receptor expression in a novel human mesangial cell line. J Am Soc Nephrol 1999; 10:2314-2322. Inflammatory cytokines upregulate the expression of functional CCR1 in mesangial cells.
17. 17 Rovin BH, Allred LK. Expression of Duffy antigen/receptor for chemokines (DARC) during human renal disease. J Am Soc Nephrol 1997; 8:483a.
18. 18 Liu XH, Hadley TJ, Xu L, Peiper SC, Ray PE. Up-regulation of Duffy antigen receptor expression in children with renal disease. Kidney In 1999; 55:1491-1500.
19. 19 Cockwell P, Brooks CJ, Adu D, Savage COS. Interleukin-8: A pathogenic role in antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. Kidney Int 1999; 55:852-863. In addition to examining intra-renal expression of IL-8, the authors show that ANCA can directly stimulate neutrophil production of IL-8 through Fc receptor binding. These data are used to propose a model for neutrophil retention in glomerular capillaries and subsequent endothelial injury.
20. 3CR1 antagonism.
21. •].
22. + cells, even in severe glomerular disease.
23. 23 Rovin BH, Lu L, Sedmak DD. Expression of the IL-8 receptor CXCR1 by human renal parenchymal cells and the human kidney. J Am Soc Nephrol 1998; 9:468A.
24. 24 Kato S, Luyckx VA, Ots M, Lee K-W, Ziai F, Troy JL, et al. Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int 1999; 56:1037-1048. This study provides evidence that chemokines and inflammatory cells may play a role in diabetic nephropathy.
25. 25 Mervaala EMA, Muller DN, Park J-K, Schmidt F, Lohn M, Breu V, et al. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension 1999; 33:389-395. The authors use a novel transgenic rat that contains the human renin and angiotensin genes to examine renal injury in high renin hypertension. This model displays elevated urinary MCP-1 levels, proteinuria, and interstitial monocyte infiltration, which can be reversed with angiotensin converting enzyme inhibition. These deleterious effects are not due to hypertension alone.
26. 26 Ou ZL, Natori Y, Natori Y. Gene expression of CC chemokines in experimental acute tubulointerstitial nephritis. J Lab Clin Med 1999; 133:41-47.
27. 27 Yamamoto-Shuda Y, Nakayama K, Saito T, Natori Y. Therapeutic effect of glucocorticoid on experimental crescentic glomerulonephritis. J Lab Clin Med 1999; 134:410-418.
28. 28 Schneider A, Harendza S, Zahner G, Jocks T, Wenzel U, Wolf G, et al. Cyclooxygenase metabolites mediate glomerular monocyte chemoattractant protein-1 formation and monocyte recruitment in experimental glomeruloephritis. Kidney Int 1999; 55:430-441. This study illustrates another potential reason to avoid using non-selective Cyclooxygenase inhibitors in patients with inflammatory renal disease.
29. 29 Matsukawa A, Hogaboam CM, Lukacs NW, Lincoln PM, Strieter RM, Kunkel SL. Endogenous monocyte chemoattractant protein-1 (MCP-1) protects mice in a model of acute septic peritonitis: Cross-talk between MCP-1 and leukotriene B4. J Immunol 1999; 163:6148-6154.
30. 30 Topham P, Csizmadia V, Soler D, Hines D, Gerard CJ, Salant DI, Hancock WW. Lack of chemokine receptor CCR1 enhances Th1 responses and glomerular injury during nephrotoxic nephritis. J Clin Invest 1999; 104:1549-1557. CCR1 knock out mice showed increased renal leukocyte infiltration, proteinuria, and renal injury compared to wild-type mice after induction of nephrotoxic nephritis. This unexpected outcome may be because the absence of CCR1 appears to favor a Th1 immune response. This provocative study adds another level of complexity to the issue of manipulating the chemokine network for therapeutic benefit.
31. 31 Rovin BH, Dickerson JA, Tan LC, Hebert CA. Activation of nuclear factor-kappaB correlates with MCP-1 expression by human mesangial cells. Kidney Int 1995; 48:1263-1271.
32. •].
33. •].
34. 34 Ping D, Boekhoudt GH, Rogers EM, Boss JM. Nuclear Factor-κB p65 mediates the assembly and activation of the TNF-responsive element of the murine monocyte chemoattractant-1 gene. J Immunol 1999; 162:727-734. This in-depth analysis of the MCP-1 gene 5′-flanking region confirms the requirement of two remote NF-κB sites for cytokine-mediated gene transcription. A potential mechanism for insensitivity to pyrrolidine dithiocarbamate based on NF-κB subunit composition is presented.
35. 35 Zoja C, Donadelli R, Colleoni S, Figliuzzi M, Bonazzola S, Morigi M, Remuzzi G. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-κB activation. Kidney Int 1998; 53:1608-1615.
36. 36 Ortego M, Bustos C, Hernandez-Presa MA, Tunon J, Dias C, Hernandez G, Egido J. Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999; 147:253-261. A potential beneficial effect of HMG-CoA reductase inhibitors beyond lipid lowering is presented.
37. 37 Mukaida N, Okamoto S, Ishikawa Y, Matsushima K. Molecular mechanism of interleukin-8 gene expression. J Leukoc Biol 1994; 56:554-558.
38. 38 Ruiz-Ortega M, Bustos C, Hernandez-Presa MA, Lorenzo O, Plaza JJ, Egido J. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-κB activation and monocyte chemoattractant protein-1 synthesis. J Immunol 1998; 161:430-439. In-vitro analysis of the effects of angiotensin II on MCP-1 and NF-κB expression in mesangial cells is used to explore mechanisms through which angiotenson converting enzyme inhibitors may decrease inflammation in glomerulonephritis.
39. •] show that mesangial and proximal tubular cell MCP-1 production induced by a variety of stimuli requires activation of the transcription factor NF-κB, but not AP-1. The NF-κB protein subunits involved in MCP-1 transcription are identified.
40. 40 Hisada Y, Sugaya T, Yamanouchi M, Uchida H, Fujimura H, Sakurai H, et al. Angiotensin II plays a pathogenic role in immune-mediated renal injury in mice. J Clin Invest 1999; 103:627-635. The role of angiotensin II in anti-GBM glomerulonephritis is explored by inducing nephritis in the angiotensin II type 1a receptor knockout mouse. Relevant to chemokine regulation, this receptor knockout has no effect on early (6 h) MCP-1 expression, but prevents the rise in MCP-1 after 1-2 weeks. The renin-angiotensin system is activated in this model at day 1, after which activity declines. It is interesting that the effects of angiotensin II are delayed until a more chronic phase of disease.
41. 41 Morrissey JJ, Klahr S. Differential effects of ACE and AT1 receptor inhibition on chemoattractant and adhesion molecule synthesis. Am J Physiol 1998; 274:F580-F586.
42. 42 Chen Y-M, Chien C-T, Hu-Tsai M-I, Wu K-D, Tsai C-C, Wu M-S, Tsai T-J. Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. Kidney In 1999; 56:932-943. These data may be in vivo evidence that modulation of cAMP levels can reduce chemokine expression, consistent with the effects of increasing cAMP in vitro (see Ref. [31]).
43. 43 Rovin BH, Dickerson JA, Tan LC, Fassler J. Modulation of IL-1-induced chemokine expression in human mesangial cells through alterations in redox status. Cytokine 1997; 9:178-186.
44. 44 Rangan GK, Wang Y, Tay Y-C, Harris DCH. Inhibition of nuclear factor-κB activation reduces cortical tubulointerstitial injury in proteinuric rats. Kidney Int 1999; 56:118-134. In adriamycin nephrosis the antioxidant pyrrolidine dithiocarbamate, but not N-acetylcysteine, decreased cortical NF-κB activation by 73% and reduced interstitial monocytes by 48%.
45. •]) message and protein production are dependent on this MAP kinase. Inhibition of another MAP kinase, ERK, had no effect on MCP-1 expression. Inhibiting p38 did not prevent NF-κB activation.
46. •]) by using dominant negative or constitutively active mutants of an upstream activator of p38.
47. •].
48. •].
49. •] demonstrate a synthetic molecule that blocks MCP-1 production is effective when administered orally in a murine air pouch model of inflammation, and murine SLE nephritis.
50. •].
51. 51 Xu C, Poirer B, Van Huyen J-PD, Lucchiari N, Michel O, Chevalier J, Kaveri S. Modulation of endotheial cell function by normal polyspecific human intravenous immunoglobulins. Am J Patho 1998; 153:1257-1266.
52. 52 Shoskes DA, Jones E, Garras N, Satyanarayana K. Effect of the lazaroid U-74389G on chemokine gene expression and apoptosis in renal ischemia-reperfusion injury. Trans Proc 1998; 30:974-975.
53. 53 Yang X-D, Corvalan JRF, Wang P, Roy C, Davis CG. Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for treatment of inflammatory disease states. J Leuko Biol 1999; 66:401-410. The production and validation of a humanized anti-IL-8 neutralizing antibody is described.
54. •], viral proteins that bind CC chemokines are described in detail. Although these proteins block interaction of CC chemokines with their receptors, the viral proteins have no homology with known chemokine receptors.
55. •].
56. 56 Ramdin L, Perks B, Sheron N, Shute JK. Regulation of interleukin-8 binding and function by heparin and a2-macroglobulin. Clin Exp All 1998; 28:616-624.
57. 57 Douglas MS, Ali S, Rix DA, Zhang J-G, Kirby JA. Endothelial production of MCP-1: modulation by heparin and consequences for mononuclear cell activation. Immunolology 1997; 92:512-518.
58. 58 Gong J-H, Clark-Lewis I. Antagonists of monocyte chemoattractant protein 1 identified by modification of functionally critical NH2-terminal residues. J Exp Med 1995; 181:631-640.
59. 59 McColl SR, Clark-Lewis I. Inhibition of murine neutrophil recruitment in vivo by CXC chemokine receptor antagonists. J Immunol 1999; 163:2829-2835. A truncated form of the CXC chemokine GROα is a CXCR2 antagonist that prevents neutrophil accumulation to MIP-2 injected into air pouches or the peritoneal cavity.
60. 60 Gong JH, Uguccioni M, Dewald B, Baggiolini M, Clark-Lewis I. RANTES and MCP-3 antagonists bind multiple chemokine receptors. J Biol Chem 1996; 271:10521-10627.
61. 61 Proudfoot AEI, Power CA, Hoogewerf AJ, Montjovent MO, Borlat F, Offord RE, Wells TNC. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 1996; 271:2599-2603.
62. 62 Mack M, Luckow B, Nelson PJ, Cihak J, Simmons G, Clapham PR, et al. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: A novel inhibitory mechanism of HIV infectivity. J Exp Med 1998; 187:1215-1224. This work demonstrates that chemokine receptor antagonists may not merely block receptor accessibility.
63. 63 Grone H-J, Weber C, Weber KSC, Grone EF, Rabelink T, Klier CM, et al. MetRANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J 1999; 13:1371-1383. The modified chemokine Met-RANTES decreases interstitial damage in a moderate rejection model, and synergizes with low dose cyclosporin A in a severe rejection model.
64. 64 Panzer U, Schneider A, Wilken J, Thompson DA, Kent SBH, Stahl RAK. The chemokine receptor antagonist AOP-RANTES reduces monocyte infiltration in experimental glomerulonephritis. Kidney Int 1999; 56:2107-2115. The modified chemokine AOP-RANTES, which antagonizes CCR5, reduces monocyte infiltration by 60% and collagen IV deposition by 50% in anti-thymocyte glomerulonephritis.
65. 65 Reckless J, Grainger DJ. Identification of oligopeptide sequences which inhibit migration induced by a wide range of chemokines. Biochem J 1999; 340:803-811. The authors test various peptides based on the amino acid sequence of MCP-1 for chemokine receptor antagonism. Interestingly, one of these peptides blocks not only CC, but also CXC receptors.
66. 66 Fujisawa N, Hayashi S, Kurdowska A, Carr FK, Miller EJ. Inhibition of GROa-induced human endothelial cell proliferation by the a-chemokine inhibitor antileukinate. Cytokine 1999; 11:231-238.
67. 67 Hesselgesser J, Ng HP, Liang M, Zheng W, May K, Bauman JG, et al. Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor. J Biol Chem 1998; 273:15687-15692. Drug discovery is used to identify 4-hydroxypeperidine derivatives as CCR1 antagonists, demonstrating the feasibility of designing synthetic chemokine receptor antagonists.
68. 68 Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999; 96:5698-5703. A synthetic CCR5 antagonist is described, that also has activity against CCR2 when used at higher concentrations. While this agent blocks replication of certain HIV-1 isolates, it could conceivably have a role in renal inflammation by blocking two receptors that are important in renal injury.
69. •] are the first studies to identify single nucleotide polymorphisms in the regulatory regions of chemokine genes that affect transcriptional activity of the 5′-flanking region, as well as leukocyte chemokine production. Such polymorphisms may regulate the amount of chemokine produced in the kidney during disease, and consequently, the severity of renal inflammation.
70. •].